2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

628. Aggressive Lymphomas: Cellular Therapies: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Clinical Procedures, Treatment Considerations, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Infusion, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality of Care, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult
PAPER

1913 Impact of glucagon-like peptide-1 receptor agonists on outcomes of chimeric antigen receptor T-cell therapy in diffuse large B-cell lymphoma patients.

Baldeep Wirk, MD
1 Virginia Commonwealth University, Richmond, United States

 

Background: Preclinical studies showed synergy between glucagon-like peptide-1 receptor (GLP-1R) agonists and urolithin A, which activate autophagy and mitophagy. This leads to increased CD8+ T memory cells and enhances chimeric antigen receptor T-cell (CAR T-cell) persistence and antitumor activity in vitro and in xenograft models (Cell Rep Med 2025; 6:102021). Prior studies showed GLP-1R agonist use during CAR T-cell therapy does not increase cytokine release syndrome. This study examines the impact of GLP-1R agonist use in patients with diffuse large B-cell lymphoma (DLBCL) undergoing CAR T-cell therapy on overall mortality.

Methods: This is a retrospective cohort study using the TriNetx Research Network to analyze adults aged 18 or older with DLBCL receiving CAR T-cell therapy from 2015 to 2025. Cohort 1 (n =145) received GLP-1R agonists within 6 weeks of CAR T-cell therapy and continued afterward.  Cohort 2 (n =4754) did not receive any GLP-1R agonists before or after CAR T-cell therapy. Propensity score matching (1:1) balanced age, gender, race, and relevant comorbidities such as diabetes, obesity, and ischemic heart disease between the two cohorts. The analysis used the TriNetX platform with its built-in survival and risk assessment tools.

Results:   Propensity score matching balanced baseline characteristics of cohort 1 (n =145) and cohort 2 (n =145) for age (median 64 years [IQR, 14] vs 63 years [IQR, 15]; p = 0.7), male gender (69% vs 68%; p = 0.9), white race (72% vs 77%; p = 0.3), black race (12% vs 9%; p =0.3); Asian (7% vs 7%; p = 1), Hispanic/Latino (10% vs 7%; p = 0.4), diabetes (79% vs 78%; p = 0.9), obesity (50% vs 52%; p = 0.7), ischemic heart disease (38.6% vs 39.3%; p = 0.9); prior autologous hematopoietic cell transplantation (auto-HCT) (25% vs 26%; p = 0.8); 4 prior lines of chemotherapy (21% vs 18%; p = 0.6), and lactate dehydrogenase levels (median 216 units/ liter [IQR, 97] in 93% of cohort 1 and 235 units/ liter [IQR, 139] in 94% of cohort 2, p = 0.68).  Median follow-up was 365 days [IQR 175] for cohort 1 and 365 days [IQR 195] for cohort 2. 

The 1-year mortality rate in cohort 1versus cohort 2 was 15.9% vs 28.3%, with an absolute risk reduction of 12.4% (risk difference: -0.124, 95% CI -0.22 to -0.03; p = 0.01). There was a 44% relative risk reduction in mortality in cohort 1 (risk ratio 0.56, 95% CI 0.36–0.89) and lower odds of death (odds ratio 0.48, 95% CI 0.27–0.85). Kaplan-Meier analysis showed a 1-year survival probability of 81.2% in cohort 1 vs 66.8% in cohort 2 (Log-Rank p = 0.01). Median overall survival remains not reached in either cohort. 

 

Cox proportional hazards regression model to determine the independent impact of cohort membership on overall survival showed cohort 1 had a 49% reduction in the risk of mortality versus cohort 2 (HR: 0.51; 95% CI: 0.33 – 0.77; p = 0.002).Independent predictors of worse survival included male gender (HR 1.2, 95% CI 1.1–1.3; p < 0.001), diabetes (HR 1.3, 95% CI 1.1–1.4; p < 0.001), and ischemic heart disease (HR 1.2, 95% CI 1.1–1.4; p = 0.002). Factors not independently predictive of survival included age; race (White, Black, Asian); Hispanic/ Latino ethnicity; number of previous chemotherapy lines; stage 3 or 4 lymphoma; prior autologous HCT; obesity classes 1, 2, or 3; or type of CAR T-cell therapy (lisocabtagene maraleucel, axicabatagene ciloleucel, or tisangenlecleucel).

Next-line therapy after CAR T-cell infusion was needed in 55.9% (n = 81) of cohort 1 versus 82.1% (n = 119) for cohort 2, with a significant absolute risk reduction of 26% (risk difference was -0.26, 95% CI -0.36 to - 0.16; p < 0.001) at 1 year. GLP-1R agonist use had a 32% relative risk reduction in the need for next-line therapy (risk ratio 0.68, 95% CI 0.58–0.80) and lower odds of treatment progression (odds ratio 0.28, 95% CI 0.16–0.47) at 1 year.

 

Conclusions:  There was a significant reduction in mortality with GLP-1R agonist use in DLBCL patients who had CAR T-cell therapy. These real-world clinical results support preclinical data suggesting that GLP-1R agonists enhance CAR T-cell persistence and antitumor activity, warranting prospective studies.

Baldeep Wirk, MD: No relevant conflicts of interest to declare.